Global Crohn’s Disease Treatment Market

Crohn’s Disease Treatment Comprehensive Study by Type (Drug (Anti-inflammatory drugs, Oral 5-aminosalicylates, Biologics, Antibiotics, and Other), Nutrition Therapy, Surgery), Route of Administration (Oral, Injectable), Distribution Channel (Hospitals Pharmacy, Online Pharmacy, Retail Pharmacy) Players and Region - Global Market Outlook to 2026

Crohn’s Disease Treatment Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Crohn’s Disease Treatment Market Overview:
Inflammatory bowel diseases (IBD), that includes Crohn’s disease and inflammatory bowel disease, affect as many as 1.6 million Americans, most of the affected person are diagnosed before age 35. These chronic, life-long conditions may be treated but not cured. IBD can significantly affect a patient’s quality of life and should have a high financial burden. Crohn’s disease can affect any a part of the canal, from the mouth to the anus. It most typically affects the top of the tiny intestine (the ileum) where it joins the start of the colon. Crohn’s disease may appear in patches, affecting some areas of the GI tract while leaving other sections totally untouched. In Crohn’s disease, the irritation may enlarge through the complete width of the bowel wall. The Crohn’s & Colitis Foundation of America (CCFA) stated that approximately 1.6 million Americans currently have IBD, a growth of about 200,000 since the last time CCFA reported this figure. There could also be as many as 80,000 children within the United States with IBD. Some of the players profiled in the study are AbbVie Inc. (United States), Takeda (Japan), RedHill Biopharma (Israel), Johnson & Johnson (United States), Shire (United States), Genentech (United States), Celgene (United States), Mesoblast (Australia) and Gilead (United States).

On the basis of geography, the market of Crohn’s Disease Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Route of Administration, the sub-segment i.e. Oral will boost the Crohn’s Disease Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Hospitals Pharmacy will boost the Crohn’s Disease Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Growth Drivers
  • Increasing Number of Drug Therapies for the Disease
  • Growing Number of Patients Suffering from Crohn’s Disease

Influencing Trend
  • Advanced Technologies Used For Better Diagnosis and Treatment


Opportunities
  • Rising Government To Improve The Healthcare Infrastructures
  • Increasing R&D of Novel Therapies

Challenges
  • Adoption Alternative Treatment Options Such as Ayurveda and Homeopathy




The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.

Target Audience:
Pharmaceutical Companies, Research and Development (R&D) Companies, Research Organization, Healthcare Industry, Potential Technology Investors, Regulatory & Government Bodies and Others

Major Objectives Focused through this Study
• To define, describe, and forecast the Global Crohn’s Disease Treatment market on the basis of product [Drug (Anti-inflammatory drugs, Oral 5-aminosalicylates, Biologics, Antibiotics, and Other), Nutrition Therapy and Surgery] , application [], key regions and end user
• To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
• To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
• Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
• To provide market size for various segments of the Crohn’s Disease Treatment market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
• To strategically profile the key players and analyzing their market shares and core competencies in the Crohn’s Disease Treatment industry
• To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are .
** Confirmation on availability of data would be informed prior purchase

While framing the research framework, major and emerging players operating in the Crohn’s Disease Treatment market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Report Objectives / Segmentation Covered

By Type
  • Drug (Anti-inflammatory drugs, Oral 5-aminosalicylates, Biologics, Antibiotics, and Other)
  • Nutrition Therapy
  • Surgery
By Route of Administration
  • Oral
  • Injectable

By Distribution Channel
  • Hospitals Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Number of Drug Therapies for the Disease
      • 3.2.2. Growing Number of Patients Suffering from Crohn’s Disease
    • 3.3. Market Challenges
      • 3.3.1. Adoption Alternative Treatment Options Such as Ayurveda and Homeopathy
    • 3.4. Market Trends
      • 3.4.1. Advanced Technologies Used For Better Diagnosis and Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Crohn’s Disease Treatment, by Type, Route of Administration, Distribution Channel and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Crohn’s Disease Treatment (Value)
      • 5.2.1. Global Crohn’s Disease Treatment by: Type (Value)
        • 5.2.1.1. Drug (Anti-inflammatory drugs, Oral 5-aminosalicylates, Biologics, Antibiotics, and Other)
        • 5.2.1.2. Nutrition Therapy
        • 5.2.1.3. Surgery
      • 5.2.2. Global Crohn’s Disease Treatment by: Route of Administration (Value)
        • 5.2.2.1. Oral
        • 5.2.2.2. Injectable
      • 5.2.3. Global Crohn’s Disease Treatment by: Distribution Channel (Value)
        • 5.2.3.1. Hospitals Pharmacy
        • 5.2.3.2. Online Pharmacy
        • 5.2.3.3. Retail Pharmacy
      • 5.2.4. Global Crohn’s Disease Treatment Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Crohn’s Disease Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AbbVie Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Takeda (Japan)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. RedHill Biopharma (Israel)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Johnson & Johnson (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Shire (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Genentech (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Celgene (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Mesoblast (Australia)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Gilead (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Crohn’s Disease Treatment Sale, by Type, Route of Administration, Distribution Channel and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Crohn’s Disease Treatment (Value)
      • 7.2.1. Global Crohn’s Disease Treatment by: Type (Value)
        • 7.2.1.1. Drug (Anti-inflammatory drugs, Oral 5-aminosalicylates, Biologics, Antibiotics, and Other)
        • 7.2.1.2. Nutrition Therapy
        • 7.2.1.3. Surgery
      • 7.2.2. Global Crohn’s Disease Treatment by: Route of Administration (Value)
        • 7.2.2.1. Oral
        • 7.2.2.2. Injectable
      • 7.2.3. Global Crohn’s Disease Treatment by: Distribution Channel (Value)
        • 7.2.3.1. Hospitals Pharmacy
        • 7.2.3.2. Online Pharmacy
        • 7.2.3.3. Retail Pharmacy
      • 7.2.4. Global Crohn’s Disease Treatment Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Crohn’s Disease Treatment: by Type(USD Million)
  • Table 2. Crohn’s Disease Treatment Drug (Anti-inflammatory drugs, Oral 5-aminosalicylates, Biologics, Antibiotics, and Other) , by Region USD Million (2015-2020)
  • Table 3. Crohn’s Disease Treatment Nutrition Therapy , by Region USD Million (2015-2020)
  • Table 4. Crohn’s Disease Treatment Surgery , by Region USD Million (2015-2020)
  • Table 5. Crohn’s Disease Treatment: by Route of Administration(USD Million)
  • Table 6. Crohn’s Disease Treatment Oral , by Region USD Million (2015-2020)
  • Table 7. Crohn’s Disease Treatment Injectable , by Region USD Million (2015-2020)
  • Table 8. Crohn’s Disease Treatment: by Distribution Channel(USD Million)
  • Table 9. Crohn’s Disease Treatment Hospitals Pharmacy , by Region USD Million (2015-2020)
  • Table 10. Crohn’s Disease Treatment Online Pharmacy , by Region USD Million (2015-2020)
  • Table 11. Crohn’s Disease Treatment Retail Pharmacy , by Region USD Million (2015-2020)
  • Table 12. South America Crohn’s Disease Treatment, by Country USD Million (2015-2020)
  • Table 13. South America Crohn’s Disease Treatment, by Type USD Million (2015-2020)
  • Table 14. South America Crohn’s Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 15. South America Crohn’s Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 16. Brazil Crohn’s Disease Treatment, by Type USD Million (2015-2020)
  • Table 17. Brazil Crohn’s Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 18. Brazil Crohn’s Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 19. Argentina Crohn’s Disease Treatment, by Type USD Million (2015-2020)
  • Table 20. Argentina Crohn’s Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 21. Argentina Crohn’s Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 22. Rest of South America Crohn’s Disease Treatment, by Type USD Million (2015-2020)
  • Table 23. Rest of South America Crohn’s Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 24. Rest of South America Crohn’s Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 25. Asia Pacific Crohn’s Disease Treatment, by Country USD Million (2015-2020)
  • Table 26. Asia Pacific Crohn’s Disease Treatment, by Type USD Million (2015-2020)
  • Table 27. Asia Pacific Crohn’s Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 28. Asia Pacific Crohn’s Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 29. China Crohn’s Disease Treatment, by Type USD Million (2015-2020)
  • Table 30. China Crohn’s Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 31. China Crohn’s Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 32. Japan Crohn’s Disease Treatment, by Type USD Million (2015-2020)
  • Table 33. Japan Crohn’s Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 34. Japan Crohn’s Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 35. India Crohn’s Disease Treatment, by Type USD Million (2015-2020)
  • Table 36. India Crohn’s Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 37. India Crohn’s Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 38. South Korea Crohn’s Disease Treatment, by Type USD Million (2015-2020)
  • Table 39. South Korea Crohn’s Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 40. South Korea Crohn’s Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 41. Taiwan Crohn’s Disease Treatment, by Type USD Million (2015-2020)
  • Table 42. Taiwan Crohn’s Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 43. Taiwan Crohn’s Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 44. Australia Crohn’s Disease Treatment, by Type USD Million (2015-2020)
  • Table 45. Australia Crohn’s Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 46. Australia Crohn’s Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 47. Rest of Asia-Pacific Crohn’s Disease Treatment, by Type USD Million (2015-2020)
  • Table 48. Rest of Asia-Pacific Crohn’s Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 49. Rest of Asia-Pacific Crohn’s Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 50. Europe Crohn’s Disease Treatment, by Country USD Million (2015-2020)
  • Table 51. Europe Crohn’s Disease Treatment, by Type USD Million (2015-2020)
  • Table 52. Europe Crohn’s Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 53. Europe Crohn’s Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 54. Germany Crohn’s Disease Treatment, by Type USD Million (2015-2020)
  • Table 55. Germany Crohn’s Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 56. Germany Crohn’s Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 57. France Crohn’s Disease Treatment, by Type USD Million (2015-2020)
  • Table 58. France Crohn’s Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 59. France Crohn’s Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 60. Italy Crohn’s Disease Treatment, by Type USD Million (2015-2020)
  • Table 61. Italy Crohn’s Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 62. Italy Crohn’s Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 63. United Kingdom Crohn’s Disease Treatment, by Type USD Million (2015-2020)
  • Table 64. United Kingdom Crohn’s Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 65. United Kingdom Crohn’s Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 66. Netherlands Crohn’s Disease Treatment, by Type USD Million (2015-2020)
  • Table 67. Netherlands Crohn’s Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 68. Netherlands Crohn’s Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 69. Rest of Europe Crohn’s Disease Treatment, by Type USD Million (2015-2020)
  • Table 70. Rest of Europe Crohn’s Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 71. Rest of Europe Crohn’s Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 72. MEA Crohn’s Disease Treatment, by Country USD Million (2015-2020)
  • Table 73. MEA Crohn’s Disease Treatment, by Type USD Million (2015-2020)
  • Table 74. MEA Crohn’s Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 75. MEA Crohn’s Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 76. Middle East Crohn’s Disease Treatment, by Type USD Million (2015-2020)
  • Table 77. Middle East Crohn’s Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 78. Middle East Crohn’s Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 79. Africa Crohn’s Disease Treatment, by Type USD Million (2015-2020)
  • Table 80. Africa Crohn’s Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 81. Africa Crohn’s Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 82. North America Crohn’s Disease Treatment, by Country USD Million (2015-2020)
  • Table 83. North America Crohn’s Disease Treatment, by Type USD Million (2015-2020)
  • Table 84. North America Crohn’s Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 85. North America Crohn’s Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 86. United States Crohn’s Disease Treatment, by Type USD Million (2015-2020)
  • Table 87. United States Crohn’s Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 88. United States Crohn’s Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 89. Canada Crohn’s Disease Treatment, by Type USD Million (2015-2020)
  • Table 90. Canada Crohn’s Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 91. Canada Crohn’s Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 92. Mexico Crohn’s Disease Treatment, by Type USD Million (2015-2020)
  • Table 93. Mexico Crohn’s Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 94. Mexico Crohn’s Disease Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Crohn’s Disease Treatment: by Type(USD Million)
  • Table 105. Crohn’s Disease Treatment Drug (Anti-inflammatory drugs, Oral 5-aminosalicylates, Biologics, Antibiotics, and Other) , by Region USD Million (2021-2026)
  • Table 106. Crohn’s Disease Treatment Nutrition Therapy , by Region USD Million (2021-2026)
  • Table 107. Crohn’s Disease Treatment Surgery , by Region USD Million (2021-2026)
  • Table 108. Crohn’s Disease Treatment: by Route of Administration(USD Million)
  • Table 109. Crohn’s Disease Treatment Oral , by Region USD Million (2021-2026)
  • Table 110. Crohn’s Disease Treatment Injectable , by Region USD Million (2021-2026)
  • Table 111. Crohn’s Disease Treatment: by Distribution Channel(USD Million)
  • Table 112. Crohn’s Disease Treatment Hospitals Pharmacy , by Region USD Million (2021-2026)
  • Table 113. Crohn’s Disease Treatment Online Pharmacy , by Region USD Million (2021-2026)
  • Table 114. Crohn’s Disease Treatment Retail Pharmacy , by Region USD Million (2021-2026)
  • Table 115. South America Crohn’s Disease Treatment, by Country USD Million (2021-2026)
  • Table 116. South America Crohn’s Disease Treatment, by Type USD Million (2021-2026)
  • Table 117. South America Crohn’s Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 118. South America Crohn’s Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 119. Brazil Crohn’s Disease Treatment, by Type USD Million (2021-2026)
  • Table 120. Brazil Crohn’s Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 121. Brazil Crohn’s Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 122. Argentina Crohn’s Disease Treatment, by Type USD Million (2021-2026)
  • Table 123. Argentina Crohn’s Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 124. Argentina Crohn’s Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 125. Rest of South America Crohn’s Disease Treatment, by Type USD Million (2021-2026)
  • Table 126. Rest of South America Crohn’s Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 127. Rest of South America Crohn’s Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 128. Asia Pacific Crohn’s Disease Treatment, by Country USD Million (2021-2026)
  • Table 129. Asia Pacific Crohn’s Disease Treatment, by Type USD Million (2021-2026)
  • Table 130. Asia Pacific Crohn’s Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 131. Asia Pacific Crohn’s Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 132. China Crohn’s Disease Treatment, by Type USD Million (2021-2026)
  • Table 133. China Crohn’s Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 134. China Crohn’s Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 135. Japan Crohn’s Disease Treatment, by Type USD Million (2021-2026)
  • Table 136. Japan Crohn’s Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 137. Japan Crohn’s Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 138. India Crohn’s Disease Treatment, by Type USD Million (2021-2026)
  • Table 139. India Crohn’s Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 140. India Crohn’s Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 141. South Korea Crohn’s Disease Treatment, by Type USD Million (2021-2026)
  • Table 142. South Korea Crohn’s Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 143. South Korea Crohn’s Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 144. Taiwan Crohn’s Disease Treatment, by Type USD Million (2021-2026)
  • Table 145. Taiwan Crohn’s Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 146. Taiwan Crohn’s Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 147. Australia Crohn’s Disease Treatment, by Type USD Million (2021-2026)
  • Table 148. Australia Crohn’s Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 149. Australia Crohn’s Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 150. Rest of Asia-Pacific Crohn’s Disease Treatment, by Type USD Million (2021-2026)
  • Table 151. Rest of Asia-Pacific Crohn’s Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 152. Rest of Asia-Pacific Crohn’s Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 153. Europe Crohn’s Disease Treatment, by Country USD Million (2021-2026)
  • Table 154. Europe Crohn’s Disease Treatment, by Type USD Million (2021-2026)
  • Table 155. Europe Crohn’s Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 156. Europe Crohn’s Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 157. Germany Crohn’s Disease Treatment, by Type USD Million (2021-2026)
  • Table 158. Germany Crohn’s Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 159. Germany Crohn’s Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 160. France Crohn’s Disease Treatment, by Type USD Million (2021-2026)
  • Table 161. France Crohn’s Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 162. France Crohn’s Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 163. Italy Crohn’s Disease Treatment, by Type USD Million (2021-2026)
  • Table 164. Italy Crohn’s Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 165. Italy Crohn’s Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 166. United Kingdom Crohn’s Disease Treatment, by Type USD Million (2021-2026)
  • Table 167. United Kingdom Crohn’s Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 168. United Kingdom Crohn’s Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 169. Netherlands Crohn’s Disease Treatment, by Type USD Million (2021-2026)
  • Table 170. Netherlands Crohn’s Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 171. Netherlands Crohn’s Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 172. Rest of Europe Crohn’s Disease Treatment, by Type USD Million (2021-2026)
  • Table 173. Rest of Europe Crohn’s Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 174. Rest of Europe Crohn’s Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 175. MEA Crohn’s Disease Treatment, by Country USD Million (2021-2026)
  • Table 176. MEA Crohn’s Disease Treatment, by Type USD Million (2021-2026)
  • Table 177. MEA Crohn’s Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 178. MEA Crohn’s Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 179. Middle East Crohn’s Disease Treatment, by Type USD Million (2021-2026)
  • Table 180. Middle East Crohn’s Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 181. Middle East Crohn’s Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 182. Africa Crohn’s Disease Treatment, by Type USD Million (2021-2026)
  • Table 183. Africa Crohn’s Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 184. Africa Crohn’s Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 185. North America Crohn’s Disease Treatment, by Country USD Million (2021-2026)
  • Table 186. North America Crohn’s Disease Treatment, by Type USD Million (2021-2026)
  • Table 187. North America Crohn’s Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 188. North America Crohn’s Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 189. United States Crohn’s Disease Treatment, by Type USD Million (2021-2026)
  • Table 190. United States Crohn’s Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 191. United States Crohn’s Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 192. Canada Crohn’s Disease Treatment, by Type USD Million (2021-2026)
  • Table 193. Canada Crohn’s Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 194. Canada Crohn’s Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 195. Mexico Crohn’s Disease Treatment, by Type USD Million (2021-2026)
  • Table 196. Mexico Crohn’s Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 197. Mexico Crohn’s Disease Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 198. Research Programs/Design for This Report
  • Table 199. Key Data Information from Secondary Sources
  • Table 200. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Crohn’s Disease Treatment: by Type USD Million (2015-2020)
  • Figure 5. Global Crohn’s Disease Treatment: by Route of Administration USD Million (2015-2020)
  • Figure 6. Global Crohn’s Disease Treatment: by Distribution Channel USD Million (2015-2020)
  • Figure 7. South America Crohn’s Disease Treatment Share (%), by Country
  • Figure 8. Asia Pacific Crohn’s Disease Treatment Share (%), by Country
  • Figure 9. Europe Crohn’s Disease Treatment Share (%), by Country
  • Figure 10. MEA Crohn’s Disease Treatment Share (%), by Country
  • Figure 11. North America Crohn’s Disease Treatment Share (%), by Country
  • Figure 12. Global Crohn’s Disease Treatment share by Players 2020 (%)
  • Figure 13. Global Crohn’s Disease Treatment share by Players (Top 3) 2020(%)
  • Figure 14. Global Crohn’s Disease Treatment share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 17. AbbVie Inc. (United States) Revenue: by Geography 2020
  • Figure 18. Takeda (Japan) Revenue, Net Income and Gross profit
  • Figure 19. Takeda (Japan) Revenue: by Geography 2020
  • Figure 20. RedHill Biopharma (Israel) Revenue, Net Income and Gross profit
  • Figure 21. RedHill Biopharma (Israel) Revenue: by Geography 2020
  • Figure 22. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 23. Johnson & Johnson (United States) Revenue: by Geography 2020
  • Figure 24. Shire (United States) Revenue, Net Income and Gross profit
  • Figure 25. Shire (United States) Revenue: by Geography 2020
  • Figure 26. Genentech (United States) Revenue, Net Income and Gross profit
  • Figure 27. Genentech (United States) Revenue: by Geography 2020
  • Figure 28. Celgene (United States) Revenue, Net Income and Gross profit
  • Figure 29. Celgene (United States) Revenue: by Geography 2020
  • Figure 30. Mesoblast (Australia) Revenue, Net Income and Gross profit
  • Figure 31. Mesoblast (Australia) Revenue: by Geography 2020
  • Figure 32. Gilead (United States) Revenue, Net Income and Gross profit
  • Figure 33. Gilead (United States) Revenue: by Geography 2020
  • Figure 34. Global Crohn’s Disease Treatment: by Type USD Million (2021-2026)
  • Figure 35. Global Crohn’s Disease Treatment: by Route of Administration USD Million (2021-2026)
  • Figure 36. Global Crohn’s Disease Treatment: by Distribution Channel USD Million (2021-2026)
  • Figure 37. South America Crohn’s Disease Treatment Share (%), by Country
  • Figure 38. Asia Pacific Crohn’s Disease Treatment Share (%), by Country
  • Figure 39. Europe Crohn’s Disease Treatment Share (%), by Country
  • Figure 40. MEA Crohn’s Disease Treatment Share (%), by Country
  • Figure 41. North America Crohn’s Disease Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • AbbVie Inc. (United States)
  • Takeda (Japan)
  • RedHill Biopharma (Israel)
  • Johnson & Johnson (United States)
  • Shire (United States)
  • Genentech (United States)
  • Celgene (United States)
  • Mesoblast (Australia)
  • Gilead (United States)
Select User Access Type

Key Highlights of Report


May 2021 200 Pages 86 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Crohn’s Disease Treatment Market Quantitative research analysis
Global Crohn’s Disease Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Crohn’s Disease Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Parkinson’s Disease Therapeutics Comprehensive Study by Distribution Channel (Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies), Route of Administration (Oral, Parental (Rectal, Intranasa...
$ 3650
Stye Drugs Comprehensive Study by Type (Hordeolum, Chalazion), Rout of Administration (Oral, Topical, Injectible), Prescription mode (Over-the-counter, Prescription-based), Distribution Channel (Hos...
$ 3750
Tinnitus Drug Pipeline Comprehensive Study by Type (Anti-Depressants, Anti- Anxiety, Anti-Histamines, Anti-Convulsant), Distribution Channel (Retail Pharmacies, Drug Stores, E-Commerce) Players and R...
$ 3500
Rivanol Comprehensive Study by Type (Powder, Solution), Application (Individual, Commercial), Distribution Channel (Online, Offline) Players and Region - Global Market Outlook to 2026
$ 3500
COPD Medicine Comprehensive Study by Type (Emphysema, Chronic bronchitis), Route of Administration (Inhalation, Enteral, Parenteral), Distribution Channel (Hospital pharmacy, Retail pharmacy, Online ...
$ 3750
Calcium Malate Comprehensive Study by End Users (Food and Beverages, Pharmaceutical, Nutraceutical, Animal Feed), Distribution Channel (Online (E-Commerce Stores), Offline (Speciality Stores, Hyper M...
$ 3650